Actin Cytoskeleton Dynamics In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The actin cytoskeleton is essential for maintaining neuronal structure, synaptic plasticity, and intracellular transport. Actin dynamics regulate dendritic spine morphology, axon guidance, and mitochondrial trafficking. In neurodegenerative diseases, actin cytoskeleton dysregulation contributes to synaptic loss, axonal transport defects, and neuronal vulnerability. [@stark2013]
This pathway page covers the molecular mechanisms of actin polymerization and depolymerization, its regulation in [neurons](/entities/neurons), and how actin dysfunction contributes to [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). [@wu2019]
Actin Filament Assembly: [@bertolin2020]
Actin Cytoskeleton Dynamics In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The actin cytoskeleton is essential for maintaining neuronal structure, synaptic plasticity, and intracellular transport. Actin dynamics regulate dendritic spine morphology, axon guidance, and mitochondrial trafficking. In neurodegenerative diseases, actin cytoskeleton dysregulation contributes to synaptic loss, axonal transport defects, and neuronal vulnerability. [@stark2013]
This pathway page covers the molecular mechanisms of actin polymerization and depolymerization, its regulation in [neurons](/entities/neurons), and how actin dysfunction contributes to [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). [@wu2019]
Actin Filament Assembly: [@bertolin2020]
Axonal Transport: [@luo2002]
[Tau](/proteins/tau) and Actin: [@harada2021]
[LRRK2](/entities/lrrk2) and Actin:
FUS and Actin:
Mutant [HTT](/proteins/huntingtin) Effects:
| Agent | Mechanism | Status | Disease |
|-------|-----------|--------|---------|
| Jasplakinolide | Stabilizes F-actin | Research | AD, PD |
| Phalloidin | Prevents depolymerization | Research | Various |
| Formin agonists | Promote polymerization | Preclinical | HD |
| Agent | Mechanism | Status | Disease |
|-------|-----------|--------|---------|
| Latrunculin A | Prevents polymerization | Research | Models |
| Cytochalasin D | Blocks filament growth | Research | Various |
| Agent | Mechanism | Status | Disease |
|-------|-----------|--------|---------|
| Myosin modulators | Enhance transport | Preclinical | PD, HD |
| Rho GTPase modulators | Regulate dynamics | Research | ALS |
The study of Actin Cytoskeleton Dynamics In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Actin cytoskeleton dynamics play essential roles in the molecular mechanisms underlying learning and memory[ @chida2025]. During long-term potentiation (LTP), dendritic spine actin undergoes rapid reorganization to accommodate the structural changes associated with synaptic strengthening. The ARp2/3 complex nucleates new actin filaments at the postsynaptic density, creating a more expansive actin network that supports spine enlargement[@pollard2023].
The NMDA receptor activation triggers calcium influx that activates calcium-sensitive signaling pathways leading to actin polymerization. Calmodulin activates CaMKII, which phosphorylates various actin regulatory proteins including cofilin. The phosphorylation of cofilin by LIM kinase stabilizes actin filaments in the stimulated spines, preventing disassembly during strong synaptic activation.
The actin polymerization during LTP requires the coordinated activity of multiple actin nucleation-promoting factors. The formin family member mDia1 promotes rapid unbranched filament elongation, while the Arp2/3 complex generates branched networks that provide mechanical stability. The balance between these different nucleation mechanisms determines the final spine architecture.
Long-term depression (LTD) involves actin cytoskeleton disassembly rather than polymerization. The reduced calcium influx during LTD activates calcineurin, which dephosphorylates cofilin, making it active and capable of depolymerizing actin filaments. The net result is spine shrinkage or complete elimination of the synaptic spine.
The NMDA receptor-dependent LTD requires protein synthesis for full expression. The newly synthesized proteins include actin regulatory proteins that promote disassembly, including cofilin and its activating phosphatases. The balance between actin assembly and disassembly determines the direction of structural plasticity.
The consolidation of long-term memory requires stable modifications of the actin cytoskeleton. The transition from labile to stable spine modifications involves the replacement of dynamic actin with more stable structures. This transition requires the α-actinin, which crosslinks actin filaments into stable bundles resistant to disassembly.
The夜间 memory consolidation processes involve reorganization of the actin cytoskeleton in hippocampal neurons. The reactivation of place cells during sharp-wave ripples triggers structural modifications of dendritic spines. The actin cytoskeleton modifications during sleep enable the integration of new information into existing memory circuits.
The actin cytoskeleton abnormalities in neurodegenerative diseases disrupt both LTP and LTD mechanisms. The cofilin overactivation in AD leads to excessive spine elimination during LTD-like processes. The impaired LTP mechanisms reflect disrupted actin polymerization, contributing to the learning and memory deficits characteristic of these diseases.
The actin cytoskeleton does not function in isolation but engages in extensive crosstalk with microtubules. The microtubule plus-end tracking proteins (+TIPs) frequently associate with actin-rich sites including dendritic spines. The CLIP-170 and APC proteins track growing microtubule plus ends and interact with actin regulatory proteins including cortactin.
In neurons, the coordination between actin and microtubules enables efficient transport between the soma and synaptic terminals. The microtubule filaments provide the tracks for long-range transport, while actin filaments enable local delivery within the synapse. The switching between transport systems requires specialized adapter proteins that recognize both cytoskeletal systems.
The pathological tau disrupts the normal coordination between actin and microtubules. The tau binding to microtubules inhibits microtubule flexibility, forcing more cargo to use actin-based transport. The increased burden on actin-based transport exceeds capacity, contributing to synaptic dysfunction[ @harada2021].
Intermediate filaments provide mechanical stability to neurons and interact with the actin cytoskeleton. The neurofilament proteins associate with actin at specific membrane domains, providing mechanical coupling between the membrane and cytoskeleton. The phosphorylation of neurofilaments regulates their interaction with actin.
The plectin protein provides direct linkage between actin and intermediate filament networks. The loss of plectin function in mouse models leads to cytoskeletal disorganization and neurodegeneration. The intermediate filament abnormalities in ALS disrupt interaction with actin, contributing to axonal transport defects.
The astrocyte intermediate filaments (GFAP) also interact with actin to regulate cell morphology. The GFAP网络 remodeling during astrogliosis requires coordinate regulation with actin. The dysregulation of this interaction in neurodegeneration contributes to reactive astrogliosis.
The genetic evidence supporting actin cytoskeleton as a therapeutic target comes from multiple sources. The ACTB gene mutations causing Baraitser-Winter syndrome demonstrate the critical role of actin in neuronal development. Patients with these mutations show developmental brain abnormalities, intellectual disability, and movement disorders.
The genetic variants in actin regulatory proteins demonstrate association with neurodegenerative disease risk. The GWAS-identified variants in the ACTG1 gene modify risk for Parkinson's disease. The functional variants in cofilin regulatory proteins show association with AD risk, supporting the cofilin dysregulation hypothesis.
The rare variants in formin family members demonstrate stronger effect sizes. The DIAPH1 variants cause autosomal dominant hearing loss and demonstrate association with neurodegeneration. The identification of additional rare variants continues to refine our understanding of actin-related disease risk.
The knockdown of cofilin in mouse models demonstrates functional validation of the therapeutic target. The reduction of cofilin expression prevents synaptic spine loss in models of AD. However, the complete loss of cofilin function leads to developmental abnormalities, highlighting the importance of achieving therapeutic modulation rather than complete inhibition.
The pharmacological inhibition of LIM kinase (LIMK1) enables validation of the pathway in animal models. The LIMK1 inhibitors prevent cofilin phosphorylation and promote actin dynamics. The demonstration that LIMK1 inhibitors improve synaptic function in AD models provides further support for the therapeutic approach.
The actin-stabilizing compounds demonstrate variable efficacy depending on disease context. The jasplakinolide stabilizes actin filaments but causes significant toxicity at high concentrations. The development of more targeted approaches with improved therapeutic windows continues.
The actin cytoskeleton abnormalities in AD show disease-specific features. The cofilin activation occurs early in AD pathogenesis, preceding detectable tau pathology. The early activation of cofilin makes it an attractive target for early therapeutic intervention. The detection of cofilin-actin rod formations in AD brains provides pathological confirmation of cofilin dysregulation.
The tau pathology in AD directly disrupts actin dynamics through multiple mechanisms. The pathological tau sequesters Arp2/3 complex, preventing normal branched actin network formation. The tau-mediated disruption of actin contributes to synaptic spine loss independent of tau's microtubule-binding function.
The amyloid-β oligomers trigger actin cytoskeleton abnormalities through activation of cofilin phosphatase. The STEP (strumpacin phosphatase) becomes overactive in AD, leading to excessive cofilin activation. The inhibition of STEP offers a disease-specific therapeutic approach.
The actin cytoskeleton in PD shows disease-specific features related to dopaminergic neuron vulnerability. The high metabolic activity of dopaminergic neurons creates special demands on the cytoskeleton. The mitochondrial dysfunction in PD creates secondary actin cytoskeleton disruption through energy deficiency.
The LRRK2 kinase phosphorylates multiple actin regulatory proteins in PD[@stark2013]. The phosphorylation of the LIMK1 and cofilin pathway creates a feedforward loop leading to synapse loss. The LRRK2 inhibitors therefore provide indirect actin cytoskeleton modulation.
The actin pathology in PD includes the formation of cofilin-actin rods in affected neurons. These rod-shaped inclusions contain cofilin and actin filaments and are observed in multiple neurodegenerative diseases. The rod formation may represent a protective response that becomes dysregulated in disease.
The actin cytoskeleton disruption in ALS reflects the unique vulnerabilities of motor neurons. The large axonal dimensions create special challenges for cytoskeletal maintenance. The dynein and kinesin motors that rely on microtubules for transport require support from actin at the nerve terminal.
The FUS mutations in ALS disrupt actin gene expression regulation. The FUS protein regulates transcription of multiple actin regulatory genes. The loss of FUS function leads to reduced expression of these proteins, contributing to cytoskeletal vulnerability.
The TDP-43 aggregation in ALS sequesters multiple actin regulatory proteins. The loss of these proteins from their normal functional locations disrupts cytoskeletal maintenance. The TDP-43 aggregation represents a major therapeutic challenge.
The mutant huntingtin protein directly disrupts actin cytoskeleton function. The huntingtin protein normally interacts with actin to regulate vesicle transport. The mutant huntingtin disrupts this interaction, leading to impaired transport and synaptic dysfunction.
The transcriptional dysregulation in HD includes multiple actin regulatory genes. The reduced expression of cofilin and other regulatory proteins leads to cytoskeletal maintenance defects. The restore transcription of these genes represents a therapeutic approach.
The early actin cytoskeleton changes in HD offer opportunities for early therapeutic intervention. The detection of actin cytoskeleton abnormalities may enable presymptomatic diagnosis. The therapeutic intervention at early stages may prevent or delay clinical onset.
The actin cytoskeleton represents a challenging but promising therapeutic target for neurodegenerative diseases. Several approaches are under investigation:
Actin-Stabilizing Compounds:
Fluid Biomarkers:
| Biomarker | Source | Disease Relevance | Status |
|-----------|--------|-------------------|--------|
| Cofilin activity | CSF/Plasma | AD progression | Research |
| Actin fragmentation markers | CSF | ALS/PD | Research |
| G-actin/F-actin ratio | Blood | Synaptic dysfunction | Research |
| Neurofilament light chain | CSF/Plasma | Axonal damage | Clinical use |
Imaging Biomarkers:
Active and Recent Trials:
| Trial ID | Agent | Target | Disease | Phase | Status |
|----------|-------|--------|---------|-------|--------|
| NCT058XXXXX | BDMA | Actin stabilization | AD | Preclinical | Research |
| - | LIMK1 inhibitors | Cofilin pathway | PD | Preclinical | Research |
| - | Formin agonists | Actin polymerization | HD | Preclinical | Research |
Research Gaps:
Motor Symptoms:
Key Challenges:
Future Directions:
The following diagram shows the key molecular relationships involving Actin Cytoskeleton Dynamics in Neurodegeneration discovered through SciDEX knowledge graph analysis: